Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Study of AMG 706 in Subjects With Advanced Gastrointestinal Stromal Tumors (GISTs)

This study has been completed.
Information provided by (Responsible Party):
Amgen Identifier:
First received: August 18, 2004
Last updated: April 25, 2013
Last verified: April 2013
This study will determine the safety and effectiveness of AMG 706 in patients with advanced GIST.

Condition Intervention Phase
Gastrointestinal Cancer
Drug: AMG 706
Phase 2

Amgen has indicated that access to an investigational treatment associated with this study is available outside the clinical trial.  

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: An Open Label Study of AMG 706 in Subjects With Advanced Gastrointestinal Stromal Tumors (GISTs) Who Developed Progressive Disease or Relapsed While on Imatinib Mesylate

Resource links provided by NLM:

Further study details as provided by Amgen:

Primary Outcome Measures:
  • Objective response rate as defined using modified RECIST criteria. [ Time Frame: 48 weeks treatment or until progressive disease, or unacceptable toxicity ]

Secondary Outcome Measures:
  • Progression-free survival [ Time Frame: time from randomization to progressive disease ]
  • Overall survival [ Time Frame: time to death ]
  • Time to progression [ Time Frame: time from response to progressive disease ]
  • Time to response [ Time Frame: time from first treatment to response ]
  • Patient-reported outcomes [ Time Frame: quality of life ]
  • Use of opioid analgesics after minimal 6 months treatment [ Time Frame: narcotics usage during study ]
  • Objective response by PET and tumor size/density changes at week 8 [ Time Frame: response rate at week 8 ]
  • Objective response by size changes and/or target tumor density changes at week 8 [ Time Frame: response rate at week 8 ]
  • Safety Endpoints: Incidence of adverse events (including all, serious, grade 3, grade 4 and treatment related) [ Time Frame: for duration of study ]
  • Duration of response [ Time Frame: time to respone to progression ]
  • Palliative response [ Time Frame: amelioration of symptoms ]
  • Pharmacokinetic Endpoints: 1. The AMG 706 PK parameters (Cmax, t1/2, AUC0-24, C24); 2. To explore the PK/PD relationships [ Time Frame: during specific study timepoints ]

Enrollment: 138
Study Start Date: October 2004
Study Completion Date: June 2008
Primary Completion Date: June 2006 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
AMG 125 mg daily continuously
Drug: AMG 706
AMG 706 125 mg daily for 48 weeks, or until progressive disease or unacceptable toxicity.

Detailed Description:
Expanded Access: Amgen provides expanded access for this clinical trial. Contact the Amgen Call Center (866-572-6436) for more information.

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria

  • Age ≥ 18 years;
  • Disease progression per Response Evaluation Criteria in Solid Tumors (RECIST) during previous treatment with imatinib mesylate at least 600 mg daily for at least 8 weeks, as per two independently assessed prestudy computerized tomography (CT) scans;
  • Presence of at least one measurable (per RECIST)
  • Progressing tumor lesion not previously treated with radiotherapy or embolization and evaluable by CT scan or magnetic resonance imaging (MRI);
  • Karnofsky performance status ≥ 60;
  • imatinib treatment terminated at least 7 days before study day 1;
  • Adequate hepatic, renal, and cardiac function.

Exclusion criteria:

  • Prior malignancy (other than GIST, in situ cervical cancer, or basal cell cancer of the skin) unless treated with curative intent and without evidence of disease for ≥ 3 years; cardiac disease including myocardial infarction, unstable angina, and congestive heart failure (New York Heart Association class > II),
  • uncontrolled hypertension (systolic > 145 mmHg or diastolic > 85 mmHg),
  • History of arterial thrombosis or deep vein thrombosis (including pulmonary embolus) within 1 year of study day 1;
  • Absolute neutrophil count < 1.5x109/L, platelet count < 100x109/L, hemoglobin < 9.0 g/dL;
  • Prior treatment with motesanib diphosphate or other KIT (except imatinib) or VEGF inhibitors.
  • The study was approved by the institutional review board of each participating institution, and all patients provided written informed consent before any study-related procedures were performed.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00089960

Sponsors and Collaborators
Study Director: MD Amgen
  More Information

Additional Information:
Responsible Party: Amgen Identifier: NCT00089960     History of Changes
Other Study ID Numbers: 20040110
Study First Received: August 18, 2004
Last Updated: April 25, 2013

Keywords provided by Amgen:

Additional relevant MeSH terms:
Gastrointestinal Stromal Tumors
Gastrointestinal Neoplasms
Neoplasms, Connective Tissue
Neoplasms, Connective and Soft Tissue
Neoplasms by Histologic Type
Digestive System Neoplasms
Digestive System Diseases
Gastrointestinal Diseases
Neoplasms by Site
Vitamin B Complex
Growth Substances
Physiological Effects of Drugs processed this record on April 28, 2017